Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


      © 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Bupropion-Hcl taj pharmaceuticals

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Rsia              Europe  

Bupropion HCl Manufacturers in India Suppliers Bupropion HCl Exporters Distributors Bupropion HCl api active pharmaceuticals ingredients Bupropion HCl manufacturers Side Effects bulk drugs raw material Bupropion HCl companies Side Effects Importers Bupropion HCl  Bupropion HCl  Exporters Bupropion HCl exporters FDA Bupropion HCl DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Bupropion HCl manufacturing pharmaceutical drugs pharmaceutical intermediates Bupropion HCl pharmaceutical chemicals pharmaceutical raw materials Bupropion HCl active pharmaceutical ingredients Bupropion HCl committee active pharmaceutical ingredients manufacturer Bupropion HCl Active Pharmaceutical Ingredients manufacturer Bupropion HCl exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Bupropion HCl, Bupropion HCl manufacturer India, Bupropion HCl product, Bupropion HCl products, Api preparation, Certificate of Analysis API manufacturer product, Bupropion HCl anti ulcer product, Certificate of Origin COA Bupropion HCl  COS Bupropion HCl, pharmaceutical generic, pharmaceutical drug, medical, Bupropion HCl pharma healthcare, pharma patents, contract MSDS manufacturing Trader Bupropion HCl pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Bupropion HCl expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Bupropion HCl DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Bupropion HCl ingredients, api, HIV Bupropion HCl, tablets, capsules, syrup & protein Bupropion HCl powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Bupropion HCl gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Bupropion HCl WHO, UKMHRA Approval

   PRODUCT LIST
   Home
   API >>>
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Ctom Pharma Services
   Contact  
 











































 


 












 

 

 

 

 

 

 

 

 

 

 

HOME >> API >> API List1 >> Bupropion HCl


 

 

 

Bupropion HCl CAS Number: 31677-93-7


Product Name: Bupropion HCl pdf api

Structure:

 Bupropion HCl CAS Number: 31677-93-7,Formula C13H18ClNO

Application: Antidepressant

CAS Number: 31677-93-7
Molecular Formula: C13H19Cl2NO
Molecular weight: 276.20

Chemical data
Formula C13H18ClNO
Mol. mass 239.74 g/mol
SMILES eMolecules & PubChem

Pharmacokinetic data
Bioavailability 5 to 20% in animals; no studies in humans
Metabolism Hepatic—important CYP2B6 and 2D6 involvement
Half life 20 hours
Excretion Renal (87%), fecal (10%)

Pharmacology of bupropion and its metabolites.[105][106][107][95][108]
Exposure (concentration over time; bupropion exposure = 100%) and half-life
Bupropion R,R-Hydroxy
bupropion S,S-Hydroxy
bupropion Threo-hydro
bupropion Erythro-hydro
bupropion Exposure 100% 800% 160% 310% 90%
Half-life 10 h (IR)
17 h (SR) 21 h 25 h 26 h 26 h
Inhibition potency (potency of DA uptake inhibition by bupropion = 100%)
DA uptake 100% 0% (rat) 70% (rat) 4% (rat) No data
NE uptake 27% 0% (rat) 106% (rat) 16% (rat) No data
Ser uptake 2% 0% (rat) 4%(rat) 3% (rat) No data
α3β4 nicotinic 53% 15% 10% 7% (rat) No data
α4β2 nicotinic 8% 3% 29% No data No data
α1* nicotinic 12% 13% 13% No data No data
DA = dopamine; NE = norepinephrine; Ser = serotonin.

GENERIC NAME: bupropion

DRUG CLASS AND MECHANISM:
Bupropion is an antidepressant medication that affects chemicals within the brain that nerves use to send messages to each other. These chemical messengers are called neurotransmitters. Many experts believe that depression is caused by an imbalance among the amounts of neurotransmitters that are released. Nerves, in a process referred to as reuptake, may recycle released neurotransmitters. Bupropion works by inhibiting the reuptake of dopamine, serotonin, and norepinephrine; an action that results in more dopamine, serotonin, and norepinephrine to transmit messages to other nerves. Bupropion is unique and unlike other antidepressants in that its major effect is on dopamine, an effect that is not shared by the selective serotonin reuptake inhibitors or SSRIs [for example, paroxetine (Paxil), fluoxetine (Prozac), sertraline (Zoloft)] or the tricyclic antidepressants or TCAs [for example, amitriptyline (Elavil), imipramine (Tofranil), desipramine (Norpramin)]. The FDA approved bupropion in December 1985.

PRESCRIPTION: Yes
GENERIC AVAILABLE: Yes


PREPARATIONS: Tablets: 75, 100, and 150 mg. Sustained Release tablets: 100, 150, and 200 mg. Extended Release tablets: 150 and 300 mg.

STORAGE: Tablets should be kept at room temperature, 15-25°C (59-77°F).

PRESCRIBED FOR: Bupropion is used for the management of major depression and seasonal affective disorder (depression that occurs primarily during the fall and winter). It is also prescribed for smoking cessation.

DOSING: Bupropion usually is given in one, two or three daily doses. For immediate-release tablets, no single dose should exceed 150 mg and each dose should be separated by 6 hours.For depression the recommended dose of immediate-release tablets is 100 mg 3 times daily (300 mg/day); maximum dose is 450 mg daily. The initial dose is 100 mg twice daily. The dose may be increased to 100 mg 3 times daily after three days.The initial dose of sustained-release tablets is 150 mg daily; target dose is 150 mg twice daily; maximum dose is 200 mg twice daily.The initial dose of extended-release tablets is 150 mg daily; target dose is 300 mg daily; maximum dose is 450 mg daily. Extended release tablets are administered once daily.

When used for smoking cessation, bupropion usually is started as 150 mg once daily for three days, and then the dose is increased if the patient tolerates the starting dose. Smoking is discontinued two weeks after starting bupropion therapy.

DRUG INTERACTIONS: Bupropion should be used cautiously in patients receiving drugs that reduce the threshold for seizures. Such drugs include prochlorperazine (Compazine), chlorpromazine (Thorazine), and other antipsychotic medications of the phenothiazine class. Additionally, persons who are withdrawing from benzodiazepines [for example, diazepam (Valium), alprazolam (Xanax)] are at increased risk for seizures.

PREGNANCY: There are no adequate studies of bupropion in pregnant women. In one study, there was no difference between bupropion and other antidepressants in the occurrence of birth defects. Bupropion should only be used in pregnancy if the benefit outweighs the potential risk.

NURSING MOTHERS: Bupropion is secreted in breast milk.

SIDE EFFECTS: The most common side effects associated with bupropion are agitation, dry mouth, insomnia, headache, nausea, constipation, and tremor. In some people, the agitation or insomnia is most marked shortly after starting therapy. Some patients may experience weight loss. Uncommonly, patients may experience manic episodes or hallucinations. Four of every 1000 persons who receive bupropion in doses less than 450 mg/day experience seizures. When doses exceed 450 mg/day, the risk increases ten-fold. Other risk factors for seizures include past injury to the head and medications which can lower the threshold for seizures. (See drug interactions.)

Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with depression and other psychiatric disorders. Anyone considering the use of bupropion or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be closely observed for clinical worsening, suicidality, or unusual changes in behavior.

Information Associated with Product:
DRUG DESCRIPTION
DOSAGE
OVERDOSE
SIDE EFFECTS
PRECAUTIONS
INTERACTION
CLINICAL PHARMALOGY
CONSUMERS INFORMATION
 
 
PDF DOWNLOAD WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo

Bupropion Hcl

Api Manufacturing At Taj

Acamprosate Calcium

Clomipramine Hcl

Alendronate Sodium

Clonazepam

Amitriptyline

Clopidogrel Bisulfate

Anastrozole

Danazol

Atomoxetine Hcl

Desloratadine

Balsalazide

Desmopressin Monoacetate

Bicalutamide

Divalproex Sodium

Budesonide

Dobutamine Hcl

Bupropion Hcl

Donepezil

Calcitonin

Dothiepin Hcl

Capecitabine

Entacapone

Carbamazepine

Eptifibatide

Carboplatin

Escitalopram HBr

Carisoprodol

Eszopiclone

Carvedilol

Finasteride

Cefuroxime Axetil

Flurbiprofen

Cisplatin

Fluticasone Propionate

Citalopram Hbr

Fluvoxamine Maleate

Fosphenytoin Sodium

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.